written on 01.05.2014

Novartis sees brain-atrophy data as an edge for MS pill Gilenya


Fresh off winning European backing for broader use–which could prompt more multiple sclerosis patients to switch–Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.

Latest Reports